A blood glucose meter designed to increase the accuracy of readings by measuring haematocrit has outperformed three other devices (Accu-Chek Aviva, Caresens Dual and GlucoMen Areo 2K), according to a study published by Swansea University in January 2019.
Haematocrit, the volume percentage of red blood cells in blood, is known to influence glucose values obtained by blood glucose meters. Most other meters estimate haematocrit levels, and this can lead to an overestimate or underestimated variation.
It is well known that certain population groups (young, pregnant, patients undergoing specific treatments) have varying haematocrit levels; this can in turn affect their blood glucose measurements by up to 20 per cent.
The GlucoRx HCT meter, specifically designed with insulin users in mind, facilitates a wider health check by measuring haematocrit and blood glucose levels as well as ketones, providing a more reliable result. It does this through Haematocrit Correction Technology (HCT) and a study published in the Journal of Diabetes Science and Technology by Swansea University put this technology to the test by comparing the accuracy of the meter with three others.
This study compared capillary blood samples from 100 people and compared to the plasma values obtained by reference laboratory analyser.
The researchers concluded that the performance of GlucoRx HCT meter “had the best performance due to the haematocrit correction technology employed within this meter.”
To access the study titled ‘Comparative Accuracy Evaluation of a Blood Glucose Meter With Novel Haematocrit Correction Technology, With Three Currently Used Commercially Available Blood Glucose Monitoring Systems’ click here.